Skip to main content

Table 2 Treatment outcome analysis

From: Outcome and patterns of failure after postoperative intensity modulated radiotherapy for locally advanced or high-risk oral cavity squamous cell carcinoma

Factor Associated level Cox regression analysis hazard ratio (95% CI) (p-value)
   LRRFS DMFS OS
Univariate analysis     
Age (years) >60 1.31 (0.42, 4.13) (0.64) 1.44 (0.24, 8.62) (0.69) 2.46 (0.65, 9.28) (0.18)
Sex Male 0.92 (0.27, 3.07) (0.89) 0.75 (0.12, 4.48) (0.75) 1.81 (0.39, 8.44) (0.45)
KPS ≤70 1.20 (0.32, 4.44) (0.79) 0.94 (0.11, 8.46) (0.96) 0.74 (0.16, 3.42) (0.70)
T-classification pT3-4 1.73 (0.56, 5.37) (0.34) 2.44 (0.41, 14.58) (0.33) 1.43 (0.44, 4.70) (0.55)
N-classification pN2-3 4.71 (1.27, 17.45) (0.02) 114.6 (0.06, >1000) (0.22) 4.65 (1.23, 17.63) (0.02)
AJCC stage IV 4.43 (0.97, 20.27) (0.05) 56.7 (0.04, >1000) (0.27) 4.13 (0.90, 19.10) (0.07)
Grading G3 1.82 (0.58, 5.73) (0.31) 3.4 (0.57, 20.4) (0.18) 0.89 (0.24, 3.40) (0.87)
Resection margins R1 0.65 (0.14, 2.98) (0.58) 0.78 (0.09, 6.96) (0.82) 1.73 (0.50, 5.93) (0.38)
ECE positive LN yes 2.29 (0.74, 7.14) (0.15) 3.54 (0.58, 21.4) (0.17) 2.19 (0.66, 7.27) (0.20)
Chemotherapy* yes 0.56 (0.18, 1.75) (0.32) 1.15 (0.19, 6.89) (0.88) 0.44 (0.13, 1.50) (0.20)
Flap reconstruction yes 1.92 (0.58, 6.42) (0.29) 59.4 (0.04, >1000) (0.27) 2.48 (0.66, 9.35) (0.16)
Bilateral ND yes 0.38 (0.10, 1.40) (0.15) 0.74 (0.12, 4.46) (0.75) 0.59 (0.17, 2.01) (0.40)
Gastrostomy tube yes 1.68 (0.53, 5.30) (0.38) 1.70 (0.28, 10.17) (0.56) 1.03 (0.31, 3.38) (0.96)
Time OP to RT > 6 weeks 0.59 (0.19, 1.89) (0.38) 0.73 (0.12, 4.37) (0.73) 0.68 (0.19, 2.35) (0.54)
Multivariate analysis     
N-classification pN2-3 4.71 (1.27, 17.45) (0.02) n.a. 4.65 (1.23, 17.63) (0.02)
AJCC stage IV 1.68 (0.15, 18.51) (0.67) n.a. 1.53 (0.14, 16.94) (0.73)
  1. Abbreviations: LRRFS Locoregional recurrence-free survival, DMFS Distant metastasis-free survival, OS Overall survival, OP surgery, KPS Karnowsky performance score, ECE extracapsular extention, LN lymph node, n.a. not applicable, ND neck dissection, *including treatment with cetuximab.